Source:

Press Release

August 04, 2020
1 min read
Save

EyePoint, ImprimisRx enter Dexycu commercial alliance

Source:

Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

EyePoint Pharmaceuticals and ImprimisRx have signed a commercial alliance regarding promotion of Dexycu in the United States, according to a press release.

ImprimisRx will promote Dexycu (dexamethasone intraocular suspension 9%), approved to treat postoperative inflammation after ocular surgery, to U.S. ophthalmologists, hospitals and ASCs, initially focusing on accounts that are already purchasing Tri-Moxi (triamcinolone acetonide, moxifloxacin HCl). EyePoint’s responsibilities include marketing, selling, pricing, manufacturing and contracting for Dexycu, and it will retain all commercial rights for Dexycu outside the U.S.

“Through this agreement, we are able to access the established and complementary ImprimisRx commercial operations in cataract surgery to include Dexycu as a prioritized product in its existing portfolio of product offerings,” Nancy Lurker, president and CEO of EyePoint, said in the release. “The combination of the EyePoint sales and marketing team with the depth of ImprimisRx in the cataract surgery space positions Dexycu for accelerated growth bringing its many benefits to more physicians and patients.”

Dexycu was approved by the FDA in 2018.